• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up2.00% Nasdaq Up1.66%

    Dr. Reddy's Laboratories Ltd. (RDY)

    41.82 Down 0.42(0.99%) Feb 12, 4:02PM EST
    ProfileGet Profile for:
    Dr. Reddy's Laboratories Ltd.
    8-2-337, Road No. 3
    Banjara Hills
    Hyderabad, 500034
    India - Map
    Phone: 91 40 4900 2900
    Fax: 91 40 4900 2999
    Website: http://www.drreddys.com

    Index Membership:N/A
    Industry:Drug Manufacturers - Other
    Full Time Employees:20,373

    Business Summary 

    Dr. Reddy’s Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment produces and markets finished pharmaceutical products as branded formulations or generic finished dosages. This segment also engages in biologics business. The PSAI segment develops active pharmaceutical ingredients (APIs) and intermediaries, which are used as principal ingredients for finished pharmaceutical products. This segment also offers contract research services to other companies; and manufactures and sells APIs and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the discovery, development, and commercialization of novel small molecule agents in therapeutic areas, such as anti-infective, metabolic disorders, and pain and inflammation. It also provides differentiated formulations for unmet medical needs; and a portfolio of in-licensed patented dermatology products As of March 31, 2015, this segment had 18 active products in proprietary products development pipeline that are in various stages of development. The company’s therapeutic categories primarily include gastro-intestinal, cardiovascular, pain management, oncology, dermatology, urology, and nephrology. Dr. Reddy’s Laboratories Limited has strategic partnership with GlaxoSmithKline plc to develop and market products outside India; collaboration, license and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology; and collaboration agreement with Merck Serono to develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies. The company was founded in 1984 and is headquartered in Hyderabad, India.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Dr. Reddy's Laboratories Ltd.

    Key Executives 
    Mr. Gunupati Venkateswara Prasad B.Sc. (Chem. Eng.), M.S. (Indl. Admn.), 56
    Co-Chairman, Chief Exec. Officer, Managing Director, Member of the Management Council, Member of Management Committee, Member of Stakeholders' Relationship Committee, Member of Investment Committee and Member of Corp. Social Responsibility Committee
    Mr. Kallam Satish Reddy B.Tech., M.S., 49
    Chairman of The Board, Member of The Management Council, Chairman of Management Committee, Member of Stakeholders' Relationship Committee, Member of Investment Committee and Member of Corp. Social Responsibility Committee
    Mr. Saumen Chakraborty B.Sc. (H), MBA-IIM, 55
    Pres, Chief Financial Officer, Global Head of Information Technology & Bus. Process Excellence and Member of the Management Council
    Dr. Sripada Chandrasekhar , 59
    Pres, Global Head of HR and Member of Management Council
    Mr. Abhijit Mukherjee B.Tech. (Chem.), 58
    Chief Operating Officer, Head of Global Generics & Pharmaceutical Services & Active Ingredients (“PSAI”) Bus.es and Member of the Management Council
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.